International neuroscientists reveal next frontier
International neuroscientists reveal next frontier
Media Release - University of Auckland - 16 November 2016
Five international neuroscience pioneers will outline the next frontiers in brain research in Auckland in December.
The community-focussed panel discussion on the latest international scientific developments in brain research takes place at the University of Auckland’s Fisher & Paykel Appliances Auditorium on Friday 2 December.
The panel titled, ’International Frontier: Advances in Brain Research and Treatments’, will feature renowned neuroscientists; Professor Christopher Shaw (London), Professor Anne Young (Boston), Professor Perry Bartlett (Brisbane), Professor Hanns Möhler (Zurich) and Professor Richard Faull (Auckland).
These neuroscientists are coming together to talk about their work in unravelling the mysteries of the human brain and shaping a path to a much brighter future for people and families touched by neurological disorders.
The public panel discussion is co-hosted by the Neurological Foundation of New Zealand and the Centre for Brain Research (CBR) at the University of Auckland and supported by the Freemasons Foundation.
The CBR’s Scientific Advisory Board
participating members are;
Professor
Chris Shaw
Professor of Neurology and
Neurogenetics at the Department of Basic and Clinical
Neuroscience at King's College London
Christopher
Shaw is Professor of Neurology and Neurogenetics, Head of
the Department of Clinical Neuroscience, Director of the
Medical Research Council Centre for Neurodegeneration
Research and Director of the Wohl Clinical Neuroscience
Institute at the Institute of Psychiatry, King's College
London.
He is an Honorary Consultant Neurologist at
King's College Hospital where he directs a clinic for
patients with motor neuron disease (MND, also known as
amyotrophic lateral sclerosis [ALS]). His early training in
General Medicine and Neurology was conducted in New Zealand.
He moved to the UK in 1992 on a Wellcome Trust New Zealand
Health Research Council Fellowship.
Professor Anne
Young
Distinguished Julieanne Dorn Professor
of Neurology at Harvard Medical School
Professor Anne
Young established the MassGeneral Institute for
Neurodegenerative Disease (MIND). MIND brings together
scientists at Massachusetts General Hospital concentrating
on studies of Alzheimer's, Parkinson’s disease (PD),
Huntington’s disease (HD) and ALS. Professor Young
spearheaded the comprehensive drug discovery efforts at MIND
and has been successful in identifying drug targets for PD,
HD and other neurodegenerative diseases.
Professor Young
holds membership in the Institute of Medicine, the American
Academy of Arts and Sciences. She is also the only person to
have been president of both the international Society for
Neuroscience and the American Neurological
Association.
Professor Perry
Bartlett
Professor of Molecular Neuroscience
at the Queensland Brain Institute, University of
Queensland
Professor Perry Bartlett, FAA is
internationally renowned in the field of cellular and
molecular neuroscience, as highlighted by his election as a
Fellow of the Australian Academy and awarding of an
Australian Research Council Federation Fellowship in
2003.
Professor Bartlett was appointed Foundation Chair
in Molecular Neuroscience at the University of Queensland in
2002, and the inaugural Director of the Queensland Brain
Institute in 2003. He initially introduced neuroscience into
the Walter and Eliza Hall Institute of Medical
Research.
Professor Bartlett has published more than 180
peer-reviewed papers, and is the recipient of a number of
prizes for neuroscience excellence.
Professor
Hanns Möhler
Distinguished Professor at the
Institute of Pharmacology and Toxicology of the University
of Zurich
Hanns Möhler was appointed in 1988 as the
Professor of Pharmacology and Director of the Institute of
Pharmacology in a joint appointment by the University of
Zurich (Medical Faculty) and by the Swiss Federal Institute
of Technology (ETH) Zurich (Department of Chemistry and
Applied Biosciences).
He has published nearly three
hundred full papers in scientific journals or books, is
co-author of a textbook (Biochemistry), and edited or
co-edited three books (The Challenge of Neuropharmacology,
Pharmacology of GABA and Glycine Neurotransmission, The GABA
Receptors).
He has been honoured by prestigious lecture
invitations and numerous prizes including the Neuroscience
Award of the European College of Neuropsychopharmacology,
The Ott-Prize of the Swiss Academy of Medical Sciences and
the Golden Kraepelin Medal by the Max Planck Institute of
Psychiatry in
Germany.
ENDS